Intrexon Corp (XON) 26.23 $XON
Agilis Biotherapeutics Announces FDA Orphan Drug Designation for the Treatment of Friedreich's Ataxia (FA)
BusinessWire - Tue Aug 02, 7:30AM CDT
Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Agilis' gene therapy product candidate, AGIL-FA, being developed for the treatment of Friedreich's ataxia (FA), an inherited degenerative neuromuscular disorder resulting in loss of motor coordination and strength, hearing, vision, speech and often premature death. Agilis is the first company to receive orphan designation from the FDA for a gene therapy to treat FA and it is the fourth time this year that Agilis has been granted orphan designation in the US and Europe for its gene therapies. The Company's gene therapies for AADC deficiency and Angelman syndrome have previously received orphan status.
XON: 26.23 (-1.15)
Intrexon to Announce Second Quarter and First Half 2016 Financial Results on August 9th
PR Newswire - Tue Aug 02, 7:00AM CDT
Intrexon Corporation (NYSE: XON) today announced it will release second quarter and first half 2016 financial results after the market closes on Tuesday, August 9th, 2016. The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update.
XON: 26.23 (-1.15)
ZIOPHARM to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Tuesday, August 9, 2016
GlobeNewswire - Tue Aug 02, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it will host a conference call and webcast slide presentation to discuss financial results for the quarter ended June 30, 2016 and provide a mid-year corporate update on Tuesday, August 9, 2016 at 4:30 PM ET.
ZIOP: 4.89 (-0.17), XON: 26.23 (-1.15)
GM Mosquito Release Commences in Grand Cayman
PR Newswire Europe - Thu Jul 28, 1:16PM CDT
GEORGE TOWN, Grand Cayman, July 28, 2016 /PRNewswire/ --
XON: 26.23 (-1.15)
Fibrocell to Host Conference Call and Webcast on Thursday, August 4, 2016 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights
GlobeNewswire - Thu Jul 28, 7:03AM CDT
Fibrocell Science, Inc. (NASDAQ:FCSC) will report financial results for the second quarter ended June 30, 2016 and recent operational highlights on Thursday, August 4, 2016, before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell's remarks.
FCSC: 1.04 (+0.02), XON: 26.23 (-1.15)
Fibrocell Announces First Subjects Enrolled in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
GlobeNewswire - Wed Jul 27, 3:01PM CDT
Fibrocell Science, Inc. (NASDAQ:FCSC) today announced that the first two adult subjects were enrolled in the Phase I/II clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). FCX-007 is Fibrocell's orphan gene-therapy product candidate for the treatment of RDEB, a devastating, painful, blistering skin disease with a high mortality rate.
FCSC: 1.04 (+0.02), XON: 26.23 (-1.15)
Oxitec and Piracicaba City Hall Start Downtown Release of Friendly(TM) Aedes
PR Newswire - Tue Jul 19, 8:00AM CDT
Oxitec and Piracicaba City Hall today start the release of Friendly(TM) Aedes mosquitoes in downtown Piracicaba, Brazil. São Judas is the first central neighbourhood to receive the mosquito that fights the primary vector of dengue, Zika and chikungunya. A contract for the expansion of the project was signed in late May and will benefit 10 other neighbourhoods as well. Overall, the 11 neighbourhoods host an estimated population of 60,000 residents in an area of 12.5 km2.
XON: 26.23 (-1.15)
ZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Tue Jul 19, 7:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today provided an update regarding the Company's ongoing multicenter Phase I study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma.
ZIOP: 4.89 (-0.17), XON: 26.23 (-1.15)
ZIOPHARM (ZIOP) Stock Down on Patient Death in Phase I
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:37AM CDT
ZIOPHARM (ZIOP) announced the death of a patient in a phase I study on Ad-RTS-hIL-12 in the treatment of recurrent or progressive GBM or grade III malignant glioma.
MACK: 5.72 (-0.10), ZIOP: 4.89 (-0.17), INVA: 12.84 (-0.20), XON: 26.23 (-1.15)
ZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Fri Jul 15, 8:25AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today issued the following statement regarding the Company's ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma:
ZIOP: 4.89 (-0.17), XON: 26.23 (-1.15)
Dengue Fever Cases Drop 91% in Neighbourhood of Piracicaba, Brazil, Where Oxitec's Friendly(TM) Aedes Were Released
PR Newswire Europe - Thu Jul 14, 8:01AM CDT
OXFORD, England, July 14, 2016 /PRNewswire/ --
XON: 26.23 (-1.15)
Fibrocell to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
GlobeNewswire - Thu Jul 07, 3:05PM CDT
Fibrocell Science, Inc., (NASDAQ:FCSC) today announced that David Pernock, Chairman and Chief Executive Officer of Fibrocell, will present at Cantor Fitzgerald's 2 Annual Healthcare Conference at 1:30 pm ET on Wednesday, July 13 in New York City. Prior to his presentation, Mr. Pernock will participate in a panel discussion on gene therapy at 12:15 pm ET.
FCSC: 1.04 (+0.02), XON: 26.23 (-1.15)
INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Intrexon Corporation and a Lead Plaintiff Deadline of July 5, 2016 - XON
GlobeNewswire - Fri Jun 24, 11:18AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Intrexon Corporation ("Intrexon"
(NYSE:XON) securities between May 12, 2015 and April 20, 2016.
XON: 26.23 (-1.15)
FINAL NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Intrexon Corporation and Reminds Investors with Losses to Contact the Firm
ACCESSWIRE - Fri Jun 24, 11:13AM CDT
IRVINE, CA / ACCESSWIRE / June 24, 2016 / Khang & Khang LLP (the "Firm" announces that a class action lawsuit has been filed against Intrexon Corporation ("Intrexon" or the "Company" (NYSE: XON). Investors who purchased or otherwise acquired shares between May 12, 2015 and April 20, 2016, inclusive (the "Class Period", are encouraged to contact the Firm prior to the July 5, 2016, lead plaintiff motion deadline.
XON: 26.23 (-1.15)
INTREXON DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Intrexon Corporation And Reminds Shareholders With Losses In Excess of $100,000 To Contact The Firm
ACCESSWIRE - Thu Jun 23, 5:44PM CDT
LOS ANGELES, CA / ACCESSWIRE / June 23, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Intrexon Corporation ("Intrexon" or the "Company" (NYSE: XON) concerning possible violations of federal securities laws between May 12, 2015 and April 20, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 5, 2016, lead plaintiff motion deadline.
XON: 26.23 (-1.15)
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Intrexon Corporation Investors and Encourages Investors to Contact the Firm
BusinessWire - Thu Jun 23, 1:00PM CDT
Glancy Prongay & Murray LLP ("GPM" announces that a class action lawsuit has been filed on behalf of investors who purchased Intrexon Corporation ("Intrexon" or the "Company" (NYSE: XON) securities between May 12, 2015 and April 20, 2016, inclusive (the "Class Period". Intrexon investors have until July 5, 2016 to file a lead plaintiff motion.
XON: 26.23 (-1.15)
How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 99.14 (+0.94), XON: 26.23 (-1.15), ARNA: 1.63 (-0.05), REGN: 434.90 (+0.90)
FINAL NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Intrexon Corporation And Advises Investors With Losses To Contact The Firm
ACCESSWIRE - Wed Jun 22, 5:52PM CDT
LOS ANGELES, CA / ACCESSWIRE / June 22, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Intrexon Corporation ("Intrexon" or the "Company" (NYSE: XON) concerning possible violations of federal securities laws between May 12, 2015 and April 20, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 6, 2016, lead plaintiff motion deadline.
XON: 26.23 (-1.15)
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Intrexon Corporation (XON) and Encourages Investors to Contact the Firm
BusinessWire - Wed Jun 22, 4:30PM CDT
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who acquired Intrexon Corporation (NYSE:XON) securities between May 12, 2015 and April 20, 2016 (the "Class Period".
XON: 26.23 (-1.15)
Agilis Biotherapeutics Announces FDA Orphan Drug Designation for the Treatment of Friedreich's Ataxia (FA)
BusinessWire - Tue Aug 02, 7:30AM CDT
Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Agilis' gene therapy product candidate, AGIL-FA, being developed for the treatment of Friedreich's ataxia (FA), an inherited degenerative neuromuscular disorder resulting in loss of motor coordination and strength, hearing, vision, speech and often premature death. Agilis is the first company to receive orphan designation from the FDA for a gene therapy to treat FA and it is the fourth time this year that Agilis has been granted orphan designation in the US and Europe for its gene therapies. The Company's gene therapies for AADC deficiency and Angelman syndrome have previously received orphan status.
XON: 26.23 (-1.15)
Intrexon to Announce Second Quarter and First Half 2016 Financial Results on August 9th
PR Newswire - Tue Aug 02, 7:00AM CDT
Intrexon Corporation (NYSE: XON) today announced it will release second quarter and first half 2016 financial results after the market closes on Tuesday, August 9th, 2016. The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update.
XON: 26.23 (-1.15)
ZIOPHARM to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Tuesday, August 9, 2016
GlobeNewswire - Tue Aug 02, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it will host a conference call and webcast slide presentation to discuss financial results for the quarter ended June 30, 2016 and provide a mid-year corporate update on Tuesday, August 9, 2016 at 4:30 PM ET.
ZIOP: 4.89 (-0.17), XON: 26.23 (-1.15)
GM Mosquito Release Commences in Grand Cayman
PR Newswire Europe - Thu Jul 28, 1:16PM CDT
GEORGE TOWN, Grand Cayman, July 28, 2016 /PRNewswire/ --
XON: 26.23 (-1.15)
Fibrocell to Host Conference Call and Webcast on Thursday, August 4, 2016 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights
GlobeNewswire - Thu Jul 28, 7:03AM CDT
Fibrocell Science, Inc. (NASDAQ:FCSC) will report financial results for the second quarter ended June 30, 2016 and recent operational highlights on Thursday, August 4, 2016, before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell's remarks.
FCSC: 1.04 (+0.02), XON: 26.23 (-1.15)
Fibrocell Announces First Subjects Enrolled in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
GlobeNewswire - Wed Jul 27, 3:01PM CDT
Fibrocell Science, Inc. (NASDAQ:FCSC) today announced that the first two adult subjects were enrolled in the Phase I/II clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). FCX-007 is Fibrocell's orphan gene-therapy product candidate for the treatment of RDEB, a devastating, painful, blistering skin disease with a high mortality rate.
FCSC: 1.04 (+0.02), XON: 26.23 (-1.15)
Oxitec and Piracicaba City Hall Start Downtown Release of Friendly(TM) Aedes
PR Newswire - Tue Jul 19, 8:00AM CDT
Oxitec and Piracicaba City Hall today start the release of Friendly(TM) Aedes mosquitoes in downtown Piracicaba, Brazil. São Judas is the first central neighbourhood to receive the mosquito that fights the primary vector of dengue, Zika and chikungunya. A contract for the expansion of the project was signed in late May and will benefit 10 other neighbourhoods as well. Overall, the 11 neighbourhoods host an estimated population of 60,000 residents in an area of 12.5 km2.
XON: 26.23 (-1.15)
ZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Tue Jul 19, 7:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today provided an update regarding the Company's ongoing multicenter Phase I study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma.
ZIOP: 4.89 (-0.17), XON: 26.23 (-1.15)
ZIOPHARM (ZIOP) Stock Down on Patient Death in Phase I
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:37AM CDT
ZIOPHARM (ZIOP) announced the death of a patient in a phase I study on Ad-RTS-hIL-12 in the treatment of recurrent or progressive GBM or grade III malignant glioma.
MACK: 5.72 (-0.10), ZIOP: 4.89 (-0.17), INVA: 12.84 (-0.20), XON: 26.23 (-1.15)
ZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Fri Jul 15, 8:25AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today issued the following statement regarding the Company's ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma:
ZIOP: 4.89 (-0.17), XON: 26.23 (-1.15)
Dengue Fever Cases Drop 91% in Neighbourhood of Piracicaba, Brazil, Where Oxitec's Friendly(TM) Aedes Were Released
PR Newswire Europe - Thu Jul 14, 8:01AM CDT
OXFORD, England, July 14, 2016 /PRNewswire/ --
XON: 26.23 (-1.15)
Fibrocell to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
GlobeNewswire - Thu Jul 07, 3:05PM CDT
Fibrocell Science, Inc., (NASDAQ:FCSC) today announced that David Pernock, Chairman and Chief Executive Officer of Fibrocell, will present at Cantor Fitzgerald's 2 Annual Healthcare Conference at 1:30 pm ET on Wednesday, July 13 in New York City. Prior to his presentation, Mr. Pernock will participate in a panel discussion on gene therapy at 12:15 pm ET.
FCSC: 1.04 (+0.02), XON: 26.23 (-1.15)
INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Intrexon Corporation and a Lead Plaintiff Deadline of July 5, 2016 - XON
GlobeNewswire - Fri Jun 24, 11:18AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Intrexon Corporation ("Intrexon"
(NYSE:XON) securities between May 12, 2015 and April 20, 2016. XON: 26.23 (-1.15)
FINAL NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Intrexon Corporation and Reminds Investors with Losses to Contact the Firm
ACCESSWIRE - Fri Jun 24, 11:13AM CDT
IRVINE, CA / ACCESSWIRE / June 24, 2016 / Khang & Khang LLP (the "Firm"
announces that a class action lawsuit has been filed against Intrexon Corporation ("Intrexon" or the "Company" (NYSE: XON). Investors who purchased or otherwise acquired shares between May 12, 2015 and April 20, 2016, inclusive (the "Class Period", are encouraged to contact the Firm prior to the July 5, 2016, lead plaintiff motion deadline. XON: 26.23 (-1.15)
INTREXON DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Intrexon Corporation And Reminds Shareholders With Losses In Excess of $100,000 To Contact The Firm
ACCESSWIRE - Thu Jun 23, 5:44PM CDT
LOS ANGELES, CA / ACCESSWIRE / June 23, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Intrexon Corporation ("Intrexon" or the "Company"
(NYSE: XON) concerning possible violations of federal securities laws between May 12, 2015 and April 20, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 5, 2016, lead plaintiff motion deadline. XON: 26.23 (-1.15)
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Intrexon Corporation Investors and Encourages Investors to Contact the Firm
BusinessWire - Thu Jun 23, 1:00PM CDT
Glancy Prongay & Murray LLP ("GPM"
announces that a class action lawsuit has been filed on behalf of investors who purchased Intrexon Corporation ("Intrexon" or the "Company" (NYSE: XON) securities between May 12, 2015 and April 20, 2016, inclusive (the "Class Period". Intrexon investors have until July 5, 2016 to file a lead plaintiff motion. XON: 26.23 (-1.15)
How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 99.14 (+0.94), XON: 26.23 (-1.15), ARNA: 1.63 (-0.05), REGN: 434.90 (+0.90)
FINAL NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Intrexon Corporation And Advises Investors With Losses To Contact The Firm
ACCESSWIRE - Wed Jun 22, 5:52PM CDT
LOS ANGELES, CA / ACCESSWIRE / June 22, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Intrexon Corporation ("Intrexon" or the "Company"
(NYSE: XON) concerning possible violations of federal securities laws between May 12, 2015 and April 20, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 6, 2016, lead plaintiff motion deadline. XON: 26.23 (-1.15)
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Intrexon Corporation (XON) and Encourages Investors to Contact the Firm
BusinessWire - Wed Jun 22, 4:30PM CDT
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who acquired Intrexon Corporation (NYSE:XON) securities between May 12, 2015 and April 20, 2016 (the "Class Period"
. XON: 26.23 (-1.15)
